

Lucilla Parnetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/345700/publications.pdf>

Version: 2024-02-01

332
papers

18,134
citations

16411

64
h-index

18606

119
g-index

345
all docs

345
docs citations

345
times ranked

17827
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
4	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	0.9	623
5	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	4.9	393
6	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
7	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
8	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
9	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurology, The, 2006, 5, 974-983.	4.9	289
10	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	0.6	280
11	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.4	271
12	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
13	Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Movement Disorders, 2014, 29, 1019-1027.	2.2	223
14	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
15	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
16	Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Molecular Neurodegeneration, 2017, 12, 11.	4.4	211
17	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
18	Cerebrospinal Fluid A β ₄₂ /40 Corresponds Better than A β ₄₂ to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191

#	ARTICLE	IF	CITATIONS
19	Dysphagia following Stroke. <i>European Neurology</i> , 2004, 51, 162-167.	0.6	184
20	Cerebrospinal fluid biomarkers in Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 131-140.	4.9	177
21	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Biological Psychiatry</i> , 2008, 64, 850-855.	0.7	164
22	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817.	0.4	163
23	Cerebrospinal fluid Tau/Î±synuclein ratio in Parkinson's disease and degenerative dementias. <i>Movement Disorders</i> , 2011, 26, 1428-1435.	2.2	161
24	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 235-240.	0.8	157
25	Diagnostic utility of cerebrospinal fluid Î±synuclein in Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2017, 32, 1389-1400.	2.2	157
26	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.5	154
27	Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 158-165.	2.2	151
28	Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80.	1.4	145
29	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
30	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
31	CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. <i>Neurological Sciences</i> , 2001, 22, 77-78.	0.9	139
32	Differential role of CSF alpha-synuclein species, tau, and AÎ² ²⁴² in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 53.	1.7	139
33	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
34	Cerebrospinal fluid Î²-glucocerebrosidase activity is reduced in parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 1423-1431.	2.2	132
35	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	3.9	128
36	White Matter Changes in Stroke Patients. <i>European Neurology</i> , 1999, 42, 67-75.	0.6	127

#	ARTICLE	IF	CITATIONS
37	Lysosomal Dysfunction and α -Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. <i>Movement Disorders</i> , 2016, 31, 791-801.	2.2	125
38	Mild Hyperhomocyst(e)inemia. <i>Stroke</i> , 2001, 32, 714-718.	1.0	120
39	Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. <i>Molecular Neurodegeneration</i> , 2015, 10, 15.	4.4	120
40	Longitudinal changes in CSF α -synuclein species reflect Parkinson's disease progression. <i>Movement Disorders</i> , 2016, 31, 1535-1542.	2.2	120
41	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. <i>Behavioural Brain Research</i> , 2009, 199, 108-118.	1.2	115
42	Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2025-2040.	2.2	113
43	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	3.0	111
44	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. <i>NeuroImage: Clinical</i> , 2018, 18, 167-177.	1.4	108
45	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1481-1484.	2.2	103
46	Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2041-2055.	2.2	101
47	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2008, 71, 1796-1803.	1.5	101
48	Differential role of CSF fatty acid binding protein 3, α -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	3.0	101
49	Cognitive Enhancement Therapy for Alzheimer's Disease. <i>Drugs</i> , 1997, 53, 752-768.	4.9	99
50	Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 434-445.	1.5	99
51	Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies. <i>Molecular Neurobiology</i> , 2019, 56, 1344-1355.	1.9	97
52	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
53	Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?. <i>Journal of the Neurological Sciences</i> , 2007, 257, 264-269.	0.3	96
54	Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 129-132.	2.2	93

#	ARTICLE	IF	CITATIONS
55	Performance of A β 1-40, A β 1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 229-238.	1.2	93
56	Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 798-806.	1.1	90
57	Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 747-754.	2.2	88
58	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 7.	3.0	87
59	The utility of α -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	0.6	86
60	Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2009, 30, 34-40.	1.5	85
61	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. <i>NeuroImage</i> , 2016, 124, 442-454.	2.1	85
62	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
63	Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. <i>European Journal of Neurology</i> , 2007, 14, 1176-1178.	1.7	81
64	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. <i>Amiotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 1-10.	2.3	81
65	The Vicious Cycle Between α -Synuclein Aggregation and Autophagic-Lysosomal Dysfunction. <i>Movement Disorders</i> , 2020, 35, 34-44.	2.2	77
66	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <i>Neurobiology of Aging</i> , 2019, 73, 61-67.	1.5	75
67	Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. <i>Human Brain Mapping</i> , 2017, 38, 12-26.	1.9	72
68	Epilepsy, amyloid- β , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	1.5	71
69	Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. <i>Neurological Sciences</i> , 2002, 23, s95-s96.	0.9	66
70	Are We Ready for Detecting α -Synuclein Prone to Aggregation in Patients? The Case of α -Protein-Misfolding Cyclic Amplification and α -Real-Time Quaking-Induced Conversion as Diagnostic Tools. <i>Frontiers in Neurology</i> , 2018, 9, 415.	1.1	66
71	Csf p-tau ₁₈₁ /tau ratio as biomarker for TDP pathology in frontotemporal dementia. <i>Amiotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 86-91.	1.1	65
72	Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. <i>Neurological Sciences</i> , 2004, 25, 13-17.	0.9	64

#	ARTICLE	IF	CITATIONS
73	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a "European <sc>ADNI</sc> study". <i>Journal of Internal Medicine</i> , 2016, 279, 576-591.	2.7	64
74	Activation of the Contact System in Cerebrospinal Fluid of Patients with Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 102-108.	0.6	62
75	Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. <i>Epilepsy Research</i> , 2008, 82, 223-226.	0.8	62
76	Cerebrospinal fluid β -glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. <i>Neurobiology of Disease</i> , 2009, 34, 484-486.	2.1	61
77	Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort. <i>Npj Parkinson's Disease</i> , 2018, 4, 33.	2.5	61
78	Amyloid- β : a potential link between epilepsy and cognitive decline. <i>Nature Reviews Neurology</i> , 2021, 17, 469-485.	4.9	60
79	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	1.5	59
80	Recanalization of Cervical Artery Dissection: Influencing Factors and Role in Neurological Outcome. <i>Cerebrovascular Diseases</i> , 2004, 17, 93-97.	0.8	58
81	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
82	Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1218-1223.	1.9	57
83	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	3.0	56
84	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 520-526.	1.3	55
85	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases "From pathophysiology to clinical practice. <i>Movement Disorders</i> , 2016, 31, 836-847.	2.2	54
86	Value of cerebrospinal fluid β -synuclein species as biomarker in Parkinson's diagnosis and prognosis. <i>Biomarkers in Medicine</i> , 2016, 10, 35-49.	0.6	51
87	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 40263.	1.6	51
88	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	3.0	51
89	Activation of complement and contact system in Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1971-1983.	2.2	49
90	Neurovascular territory involved in different etiological subtypes of ischemic stroke in the Perugia Stroke Registry. <i>European Journal of Neurology</i> , 2003, 10, 361-365.	1.7	49

#	ARTICLE	IF	CITATIONS
91	CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1281-1288.	1.2	49
92	Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 148-157.	2.2	48
93	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1023-1037.	4.0	48
94	Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2013-2023.	2.2	47
95	Early admission to stroke unit influences clinical outcome. <i>European Journal of Neurology</i> , 2006, 13, 250-255.	1.7	45
96	Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson's Disease Patients. <i>NeuroMolecular Medicine</i> , 2012, 14, 84-90.	1.8	45
97	Î±-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies. <i>Neurology</i> , 2022, 99, 195-205.	1.5	45
98	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1321-1333.	1.2	44
99	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	1.4	44
100	Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2057-2062.	2.2	42
101	Radioligand binding assay of M1-M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. <i>Journal of Neuroimmunology</i> , 1999, 99, 224-229.	1.1	41
102	THE PERUGIA HOSPITAL-BASED STROKE REGISTRY: REPORT OF THE 2ND YEAR. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 485-491.	0.5	41
103	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
104	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
105	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
106	Clinical Pharmacokinetics of Drugs for Alzheimer's Disease. <i>Clinical Pharmacokinetics</i> , 1995, 29, 110-129.	1.6	38
107	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. <i>Human Brain Mapping</i> , 2016, 37, 2114-2132.	1.9	38
108	Parkinson's and Lewy body dementia CSF biomarkers. <i>Clinica Chimica Acta</i> , 2019, 495, 318-325.	0.5	38

#	ARTICLE	IF	CITATIONS
109	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. <i>NeuroImage</i> , 2020, 218, 116932.	2.1	38
110	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38
111	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2012, 7, e48783.	1.1	37
112	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
113	Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. <i>Neurology</i> , 2000, 54, 735-735.	1.5	35
114	Pharmacological treatment of non-cognitive disturbances in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2063-2069.	2.2	34
115	Is Ultrasound Examination Sufficient in the Evaluation of Patients with Internal Carotid Artery Severe Stenosis or Occlusion?. <i>Cerebrovascular Diseases</i> , 2003, 15, 173-176.	0.8	34
116	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. <i>Human Brain Mapping</i> , 2015, 36, 3516-3527.	1.9	34
117	Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment. <i>Applied Neuropsychology Adult</i> , 2018, 25, 237-248.	0.7	34
118	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
119	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. <i>Cells</i> , 2021, 10, 1930.	1.8	34
120	A magnetization transfer study of mild and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 471-477.	1.7	33
121	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019, 77, 112-127.	1.5	33
122	The region 11 of Alzheimer amyloid- β is critical for activation of contact-kinin system. <i>Neurobiology of Aging</i> , 2001, 22, 63-69.	1.5	32
123	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. <i>Experimental Neurology</i> , 2007, 207, 218-226.	2.0	32
124	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. <i>Movement Disorders</i> , 2016, 31, 830-835.	2.2	32
125	Fingerprinting Alzheimer's Disease by ¹ H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 1696-1705.	1.8	32
126	Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimer's Disease. <i>Molecular Medicine</i> , 2007, 13, 542-550.	1.9	31

#	ARTICLE	IF	CITATIONS
127	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. <i>Scientific Reports</i> , 2019, 9, 8898.	1.6	31
128	Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 594.	1.0	31
129	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
130	Vascular Dementia: The Role of Cerebral Infarcts. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, S38-S48.	0.6	30
131	Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats. <i>Brain Research</i> , 2006, 1120, 183-190.	1.1	30
132	Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 122-129.	1.0	30
133	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
134	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. <i>Movement Disorders</i> , 2022, 37, 669-683.	2.2	30
135	Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 372-380.	1.0	29
136	Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. <i>Movement Disorders</i> , 2008, 23, 468-470.	2.2	29
137	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
138	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4958.	1.8	28
139	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 55-67.	1.2	27
140	Stroke Related to Carotid Artery Dissection in a Young Patient with Takayasu Arteritis, Systemic Lupus erythematosus and Antiphospholipid Antibody Syndrome. <i>Cerebrovascular Diseases</i> , 2002, 13, 67-69.	0.8	26
141	Effect of MTHFR Polymorphisms on Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients. <i>NeuroMolecular Medicine</i> , 2007, 9, 249-254.	1.8	26
142	The added value of A β ₂₄₂ /A β ₂₄₀ in the CSF signature for routine diagnostics of Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019, 494, 71-73.	0.5	26
143	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. <i>Neurobiology of Aging</i> , 2019, 73, 9-20.	1.5	26
144	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26

#	ARTICLE	IF	CITATIONS
145	Secondary Prevention of Stroke in Patients with Atrial Fibrillation: Factors Influencing the Prescription of Oral Anticoagulation at Discharge. <i>Cerebrovascular Diseases</i> , 2006, 21, 372-379.	0.8	25
146	Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies. <i>Future Neurology</i> , 2018, 13, 199-207.	0.9	25
147	Dissecting the Interactions between Human Serum Albumin and β -Synuclein: New Insights on the Factors Influencing β -Synuclein Aggregation in Biological Fluids. <i>Journal of Physical Chemistry B</i> , 2019, 123, 4380-4386.	1.2	25
148	The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. <i>Biomolecules</i> , 2020, 10, 335.	1.8	25
149	THE INFLAMMATORY RESPONSE IN CEREBRAL ISCHEMIA: FOCUS ON CYTOKINES IN STROKE PATIENTS. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 535-542.	0.5	24
150	Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting. <i>Scientific World Journal</i> , The, 2009, 9, 961-966.	0.8	24
151	A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline. <i>European Journal of Neurology</i> , 2011, 18, 1263-1265.	1.7	24
152	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020, 91, 88-111.	1.5	24
153	Time trends, frequency, characteristics and prognosis of short-duration transient global amnesia. <i>European Journal of Neurology</i> , 2020, 27, 887-893.	1.7	24
154	Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics. <i>Frontiers in Neurology</i> , 2020, 11, 199.	1.1	24
155	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
156	Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. <i>Biological Psychiatry</i> , 1993, 34, 380-385.	0.7	23
157	First-Ever Stroke and Outcome in Patients Admitted to Perugia Stroke Unit: Predictors for Death, Dependency, and Recurrence of Stroke within the First Three Months. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 287-294.	0.5	23
158	Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2014, 9, e101453.	1.1	23
159	Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. <i>Frontiers in Neurology</i> , 2015, 6, 143.	1.1	23
160	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170.	1.2	23
161	Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 771-780.	1.5	23
162	Plasma A β 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23

#	ARTICLE	IF	CITATIONS
163	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. <i>Neural Regeneration Research</i> , 2021, 16, 36.	1.6	23
164	Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction?. <i>Journal of Neuroimmunology</i> , 2001, 121, 126-131.	1.1	22
165	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. <i>European Journal of Pharmacology</i> , 2006, 545, 65-72.	1.7	22
166	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
167	Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism. <i>Journal of the Neurological Sciences</i> , 2015, 353, 1-8.	0.3	21
168	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. <i>Epilepsy and Behavior</i> , 2019, 101, 106592.	0.9	21
169	Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. <i>Neurological Sciences</i> , 2003, 24, 199-200.	0.9	20
170	Associations of Alzheimer's disease with macular degeneration. <i>Frontiers in Bioscience - Elite</i> , 2017, 9, 174-191.	0.9	20
171	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	0.9	20
172	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. <i>Stroke</i> , 2019, 50, 2555-2557.	1.0	20
173	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	1.7	20
174	Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. <i>Clinica Chimica Acta</i> , 2019, 494, 74-78.	0.5	20
175	Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. <i>European Journal of Neurology</i> , 2020, 27, 475-483.	1.7	20
176	Immunological Profile of Silent Brain Infarction and Lacunar Stroke. <i>PLoS ONE</i> , 2013, 8, e68428.	1.1	20
177	Arterial Hypertension and Stroke Prevention: An Update. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 317-326.	0.5	19
178	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140537.	1.1	19
179	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. <i>Frontiers in Neuroscience</i> , 2021, 15, 672954.	1.4	19
180	Evolutionary Trends in Carotid Atherosclerotic Plaques: Results of a Two-Year Follow-up Study Using an Ultrasound Imaging System. <i>Angiology</i> , 1988, 39, 429-436.	0.8	18

#	ARTICLE	IF	CITATIONS
181	CSF levels of β -amyloid 1 β 42, tau and phosphorylated tau protein in CADASIL. <i>European Journal of Neurology</i> , 2008, 15, 1252-1255.	1.7	18
182	A Combination of CSF Tau Ratio and Midsagittal Midbraintopons Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 195-203.	1.2	18
183	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 277-291.	1.2	18
184	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
185	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
186	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <i>Clinica Chimica Acta</i> , 2019, 491, 81-84.	0.5	18
187	Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. <i>Clinica Chimica Acta</i> , 2019, 495, 13-24.	0.5	18
188	Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. <i>Toxins</i> , 2021, 13, 881.	1.5	18
189	The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1659-1666.	1.2	17
190	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 647783.	1.4	17
191	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4440.	1.8	17
192	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9753.	1.8	17
193	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-12.	1.1	16
194	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016, 11, 65.	4.4	16
195	The Italian version of cognitive function instrument (CFI): reliability and validity in a cohort of healthy elderly. <i>Neurological Sciences</i> , 2018, 39, 111-118.	0.9	16
196	T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 80, 91-98.	1.5	16
197	A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. <i>Diagnostics</i> , 2020, 10, 1015.	1.3	16
198	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. <i>Frontiers in Immunology</i> , 2021, 12, 644294.	2.2	16

#	ARTICLE	IF	CITATIONS
199	Multicenter clinical placebo-controlled study with acetyl-L-carnitine (LAC) in the treatment of mildly demented elderly patients. <i>Drug Development Research</i> , 1988, 14, 213-216.	1.4	15
200	Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. <i>Aging Clinical and Experimental Research</i> , 1994, 6, 201-207.	1.4	15
201	GENETICS OF ISCHEMIC STROKE. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 531-534.	0.5	15
202	CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-6.	1.1	15
203	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. <i>Brain Sciences</i> , 2019, 9, 213.	1.1	15
204	Platelet MAO-B activity and vitamin B12 in old age dementias. <i>Molecular and Chemical Neuropathology</i> , 1992, 16, 23-32.	1.0	14
205	CSF monoamine metabolites in old age dementias. <i>Molecular and Chemical Neuropathology</i> , 1992, 16, 143-157.	1.0	14
206	Headache associated with acute ischemic stroke. <i>Journal of Headache and Pain</i> , 2001, 2, 25-29.	2.5	14
207	High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. <i>Amino Acids</i> , 2021, 53, 435-449.	1.2	14
208	Arterial Hypertension and Cognitive Dysfunction in Physiologic and Pathologic Aging of the Brain. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 158-164.	0.7	13
209	Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study. <i>Stroke Research and Treatment</i> , 2018, 2018, 1-9.	0.5	13
210	CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 3.	2.0	13
211	Changes of olfactory tract in Parkinson's disease: a DTI tractography study. <i>Neuroradiology</i> , 2021, 63, 235-242.	1.1	13
212	Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study. <i>PLoS ONE</i> , 2014, 9, e96806.	1.1	13
213	Spatial cognition in Parkinson's disease and neurodegenerative dementias. <i>Cognitive Processing</i> , 2006, 7, 77-78.	0.7	12
214	Risk Factors and Stroke Subtypes: Results of Five Consecutive Years of the Perugia Stroke Registry. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 279-286.	0.5	12
215	Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2011, 5, 479-484.	0.6	12
216	Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	1.1	12

#	ARTICLE	IF	CITATIONS
217	Prestroke dementia in patients with atrial fibrillation. <i>Journal of Neurology</i> , 2005, 252, 1504-1509.	1.8	11
218	Characteristics of Delayed Admission to Stroke Unit. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 405-411.	0.5	11
219	Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No?. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 323-335.	1.2	11
220	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. <i>Neurological Sciences</i> , 2017, 38, 83-91.	0.9	11
221	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
222	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020, 131, 2716-2731.	0.7	11
223	Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography-angiography. <i>European Journal of Neurology</i> , 2021, 28, 2185-2191.	1.7	11
224	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2022, 115, 88-108.	1.5	11
225	BRAIN CT-SCAN IN ACUTE STROKE PATIENTS: SILENT INFARCTS AND RELATION TO OUTCOME. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 669-676.	0.5	10
226	Efficacy of Thrombolytic (rt-PA) Therapy in Old Stroke Patients: The Perugia Stroke Unit Experience. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 397-404.	0.5	10
227	Diagnostic utility of CSF β -synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2016, 6, e011113.	0.8	10
228	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
229	Therapeutic options in dementia. <i>Journal of Neurology</i> , 2000, 247, 163-168.	1.8	9
230	HEART-BRAIN RELATIONSHIP: ATRIAL FIBRILLATION AND STROKE. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 493-499.	0.5	9
231	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. <i>Neurological Sciences</i> , 2015, 36, 751-757.	0.9	9
232	Serum neurofilament light chain as a preclinical marker of neurodegeneration. <i>Lancet Neurology</i> , The, 2019, 18, 1070-1071.	4.9	9
233	Levodopa treatment in Parkinson's disease: earlier or later?. <i>Annals of Translational Medicine</i> , 2019, 7, S189-S189.	0.7	9
234	Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factors. <i>Frontiers in Bioscience</i> , 2021, 26, 1075.	0.8	9

#	ARTICLE	IF	CITATIONS
235	Early manifestations of dementing illness: Treatment with glycosaminoglycan polysulfate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, 661-676.	2.5	8
236	Selection of thrombogenic antiphospholipid antibodies in cerebrovascular disease patients. <i>Journal of Neurology</i> , 2003, 250, 593-597.	1.8	8
237	Early detection of dementia in clinical practice. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 123-128.	2.2	8
238	Educational Approach on Stroke Training in Europe. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 433-437.	0.5	8
239	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 117-123.	3.0	8
240	The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up. <i>Neurological Sciences</i> , 2019, 40, 2147-2153.	0.9	8
241	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
242	Extracranial Carotid Atherosclerosis Evaluation and Stroke Occurrence: Role of the Echotomographic Analysis. <i>Angiology</i> , 1988, 39, 705-713.	0.8	7
243	Glycosaminoglycan Polysulfate in Primary Degenerative Dementia. <i>Neuropsychobiology</i> , 1995, 31, 76-80.	0.9	7
244	Clinical and genetic analysis of hereditary and sporadic ataxia in central Italy. <i>Brain Research Bulletin</i> , 2001, 56, 363-366.	1.4	7
245	Stroke Prevention and Statin Treatment. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 335-344.	0.5	7
246	Association Between Migraine and Headache Attributed to Stroke: A Case-Control Study. <i>Headache</i> , 2008, 48, 1468-1475.	1.8	7
247	Origin of Î±-mannosidase activity in CSF. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 87, 34-37.	1.2	7
248	Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. <i>Biomarker Insights</i> , 2020, 15, 117727192096407.	1.0	7
249	PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study. <i>BMC Neurology</i> , 2022, 22, 25.	0.8	7
250	Hemorheologic Factors in the Postacute Phase of Ischemic Stroke. <i>Angiology</i> , 1988, 39, 437-448.	0.8	6
251	Vertebral Artery Dissection and Hyperhomocysteinemia: A Case Report. <i>Cerebrovascular Diseases</i> , 2000, 10, 9-11.	0.8	6
252	HYPERHOMOCYSTEINEMIA: A RISK FACTOR FOR CEREBROVASCULAR DISEASE. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 501-509.	0.5	6

#	ARTICLE	IF	CITATIONS
253	Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke: A Ghost from the Past or a New Frontier?. Stroke Research and Treatment, 2010, 2010, 1-8.	0.5	6
254	Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease. Neurological Sciences, 2012, 33, 201-208.	0.9	6
255	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment. Journal of Alzheimer's Disease, 2018, 64, S281-S287.	1.2	6
256	Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?. Alzheimer's Research and Therapy, 2020, 12, 121.	3.0	6
257	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. Journal of Neurology, 2022, 269, 3129-3135.	1.8	6
258	NfL as Analogue of C-Reactive Protein in Neurologic Diseases. Neurology, 2022, 98, 911-912.	1.5	6
259	BRAIN CT SCAN IN ACUTE ISCHEMIC STROKE: EARLY SIGNS AND FUNCTIONAL OUTCOME. Clinical and Experimental Hypertension, 2002, 24, 687-696.	0.5	5
260	Secondary Prevention of Cardioembolic Stroke: Oldest and Newest Promises. Clinical and Experimental Hypertension, 2006, 28, 413-420.	0.5	5
261	Atherosclerosis Assessment Confounders in the Rancho Bernardo Study. American Journal of Cardiology, 2007, 99, 876.	0.7	5
262	Estimating the Inheritance of Frontotemporal Lobar Degeneration in the Italian Population. Journal of Alzheimer's Disease, 2014, 41, 371-376.	1.2	5
263	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. Journal of Alzheimer's Disease, 2019, 72, 1193-1207.	1.2	5
264	Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation. Journal of Parkinson's Disease, 2020, 10, 927-934.	1.5	5
265	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
266	Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability. Neurological Sciences, 2021, 42, 4309-4315.	0.9	5
267	Haemorheological Markers in 89 Patients with Stage II Peripheral Vascular Disease (PVD). Angiology, 1986, 37, 460-466.	0.8	4
268	Influence of Dementia on Antithrombotic Therapy Prescribed before Stroke in Patients with Atrial Fibrillation. Cerebrovascular Diseases, 2006, 21, 401-407.	0.8	4
269	Factors Influencing Depression Endpoints Research (FINDER): Baseline results of Italian patients with depression. Annals of General Psychiatry, 2009, 8, 14.	1.2	4
270	Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis. Movement Disorders, 2016, 31, 769-770.	2.2	4

#	ARTICLE	IF	CITATIONS
271	New <sc>CSF</sc> biomarkers on the block. EMBO Molecular Medicine, 2016, 8, 1118-1119.	3.3	4
272	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinsonâ€™s disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2017, 7, e018177.	0.8	4
273	[P4â€™157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€™OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.4	4
274	An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders. Behavioural Neurology, 2022, 2022, 1-20.	1.1	4
275	PHOSPHOLIPID AUTOANTIBODIES: TIME FOR A NEW IMMUNO-ASSAY?. Clinical and Experimental Hypertension, 2002, 24, 511-516.	0.5	3
276	Headache and ischemic stroke. Journal of Headache and Pain, 2002, 3, 15-20.	2.5	3
277	Multimodal Use of Computed Tomography in Early Acute Stroke, Part 2. Clinical and Experimental Hypertension, 2006, 28, 427-431.	0.5	3
278	Teaching Neuro <i>Images</i> : Acute tetraparesis. Neurology, 2009, 73, e58.	1.5	3
279	Hot water epilepsy and McCuneâ€™Albright syndrome: A case report. Seizure: the Journal of the British Epilepsy Association, 2009, 18, 161-162.	0.9	3
280	Biochemical diagnosis of neurodegenerative diseases gets closer. Lancet Neurology, The, 2011, 10, 203-205.	4.9	3
281	Case of posterior cortical atrophy (PCA) evolved to PCA-CBS. BMJ Case Reports, 2018, 2018, bcr-2018-224312.	0.2	3
282	Drug-induced Creutzfeldt-Jakob disease-like syndrome: early CSF analysis as useful tool for differential diagnosis. BMJ Case Reports, 2018, 11, e224314.	0.2	3
283	The issue of waste disposal in Parkinson's disease pathogenesis. Movement Disorders, 2019, 34, 985-985.	2.2	3
284	HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version. Journal of Neurology, 2021, 268, 4789-4795.	1.8	3
285	Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases. Frontiers in Neurology, 2021, 12, 800524.	1.1	3
286	Clinical and genetic analysis of an Italian family with Machado-Joseph disease. Journal of Neurology, 2001, 248, 717-719.	1.8	2
287	Cholinesterase Inhibitors: From Weapons, to Pesticides, to Cognition Enhancing Drugs. Current Enzyme Inhibition, 2006, 2, 249-259.	0.3	2
288	Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?. International Journal of Alzheimer's Disease, 2010, 2010, 1-2.	1.1	2

#	ARTICLE	IF	CITATIONS
289	Lysosomal enzymes in PD: Further evidence is needed. <i>Movement Disorders</i> , 2014, 29, 1329-1329.	2.2	2
290	Relationship between haemorheological factors and initial mental deterioration in the elderly. A preliminary study. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 5, 361-371.	0.9	2
291	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. <i>Clinica Chimica Acta</i> , 2020, 506, 55-66.	0.5	2
292	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α -synuclein measurement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1653-1661.	1.4	2
293	Glycosaminoglycans and Analogs in Neurodegenerative Disorders. , 2008, , 231-245.		2
294	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6922.	1.8	2
295	Pharmacokinetic Profile and Endocrine Effects of Posatirelin Treatment in Healthy Elderly Subjects. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 823-831.	1.0	1
296	Trattamento combinato neurochirurgico ed endovascolare di fistola durale complessa tipo III del seno longitudinale superiore e del seno marginale paratorcolare. <i>The Neuroradiology Journal</i> , 2001, 14, 245-249.	0.1	1
297	Multimodal Use of Computed Tomography in Early Acute Stroke, Part 1. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 421-426.	0.5	1
298	Cerebrospinal fluid biomarkers and white matter lesions: can we know more?. <i>European Journal of Neurology</i> , 2010, 17, 521-521.	1.7	1
299	Idebenone: a guide to its use in Alzheimer's disease, other age-related cognitive disorders and Friedreich's ataxia. <i>Drugs and Therapy Perspectives</i> , 2010, 26, 1-5.	0.3	1
300	Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers. <i>Clinical Biochemistry</i> , 2019, 72, 24-29.	0.8	1
301	A blood test for Alzheimer's disease: a step forward. <i>Lancet Neurology</i> , The, 2021, 20, 691-693.	4.9	1
302	Multiple drug interactions induced hyperammonemic encephalopathy in Dravet Syndrome. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119144.	0.3	1
303	Refractory focal non-convulsive status epilepticus in anti-glur2 encephalitis: Neuro-inflammation and AMPA receptors modulation as target treatment. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119118.	0.3	1
304	Blood biomarkers may distinguish among dementia disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 571-571.	0.9	1
305	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). <i>Neurological Sciences</i> , 2022, 43, 4221-4229.	0.9	1
306	Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	1.2	1

#	ARTICLE	IF	CITATIONS
307	Ruolo della spettroscopia protonica nella malattia di Alzheimer. <i>The Neuroradiology Journal</i> , 2000, 13, 57-60.	0.1	0
308	Lysosomal enzyme activities in human brain. <i>Journal of Biotechnology</i> , 2014, 185, S7.	1.9	0
309	Baseline CSF A β ₂ , A β ₂ /T-TAU and A β ₂ /P-tau distributions to classify pharmacog MCI patients. <i>Neurobiology of Aging</i> , 2016, 39, S30.	1.5	0
310	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. <i>Clinica Chimica Acta</i> , 2020, 502, 199-200.	0.5	0
311	Welcome to the New Open Access NeuroSci. <i>NeuroSci</i> , 2020, 1, 15-16.	0.4	0
312	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated segmentation in old and young healthy volunteers. <i>Alzheimer's and Dementia</i> , 2020, 16, e040322.	0.4	0
313	Which pre-analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. <i>Alzheimer's and Dementia</i> , 2020, 16, e045060.	0.4	0
314	CSF AD-like profile in SCD, pre-MCI and MCI subjects: Application of the A/T/N classification model in a retrospective cohort from a memory clinic. <i>Alzheimer's and Dementia</i> , 2020, 16, e043990.	0.4	0
315	The Italian dementia with lewy bodies study group (DLB-SINDEM): A multicenter survey on the accuracy and the prevalence of DLB diagnosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117651.	0.3	0
316	Cognitive decline in late-onset epilepsy of undefined etiology: A longitudinal cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117709.	0.3	0
317	Interleukin-17 axis in the modulation of cortical and subcortical synaptic plasticity across disease stages in experimental multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117746.	0.3	0
318	The "no evidence of disease activity" (NEDA) concept in MS: Impact of spinal cord MRI. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118117.	0.3	0
319	A CSF biomarker of intrathecal B cells activation correlates with memory impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117772.	0.3	0
320	Cerebrospinal fluid A/T/(N) profile and mild cognitive impairment in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119559.	0.3	0
321	Late-onset epilepsy with unknown etiology: Neuropsychological profile, cerebrospinal fluid biomarkers, and quantitative EEG characteristics. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119123.	0.3	0
322	Cerebrospinal fluid in Alzheimer's: A precious tool. <i>Oncotarget</i> , 2017, 8, 3770-3770.	0.8	0
323	Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
324	Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 83-92.	0.4	0

#	ARTICLE	IF	CITATIONS
325	A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
326	Title is missing!. , 2020, 17, e1003289.		0
327	Title is missing!. , 2020, 17, e1003289.		0
328	Title is missing!. , 2020, 17, e1003289.		0
329	Title is missing!. , 2020, 17, e1003289.		0
330	Title is missing!. , 2020, 17, e1003289.		0
331	Title is missing!. , 2020, 17, e1003289.		0
332	Title is missing!. , 2020, 17, e1003289.		0